BIOCORP and NOVO NORDISK Strengthen Their Partnership With a New Agreement on Mallya® Smart Sensor
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR),
a French company specialized in the design, development, and
manufacturing of innovative medical devices, announces the
signature of a partnership agreement with Novo Nordisk for the
commercialization of Mallya, initially in Japan.
This new agreement is reinforcing the partnership between Novo
Nordisk and BIOCORP focused on development of the Mallya product
announced in September 2021. Whereas this first development
agreement was covering brands in the insulin space only, an
additional therapeutic area in which Novo Nordisk has a presence
has been included earlier this year.
Mallya (a non-medical device in Japan) is a smart sensor that
directly attaches to the Novo Nordisk FlexTouch® insulin pens.
Mallya will enable patients with diabetes using FlexTouch® pens to
automatically collect and record daily insulin injection data such
as the number of insulin units, the date, and the time. Thanks to a
mobile application linked to Mallya, patients will be able to track
their injection history and follow their treatment in real-time.
Mallya is compatible with all Novo Nordisk FlexTouch® insulin
Based on the agreement, Novo Nordisk will be commercializing
Mallya in Japan from the first half of 2023.
“Earlier this year, we launched the first ever smart insulin
pens* in Japan (NovoPen® 6 and NovoPen Echo® Plus). However, most
of our patients today in Japan use insulin with FlexTouch®. As
such, we are very pleased by working with BIOCORP, which
manufactures and imports Mallya, to offer digital health to even
more patients” said Kasper Bødker Mejlvang, President and
Representative Director of Novo Nordisk Pharma, about the
* Smart insulin pen: a generic term for insulin pens which can
automatically record insulin dosing data (time, quantity) and
wirelessly transfer the data to mobile apps, etc. installed in
“We are very proud of this commercial launch in Japan through
our partner Novo Nordisk. Japan is among the leading countries in
the use of diabetes management devices and monitoring devices. This
is a natural and high potential market for Mallya. In addition to
that launch, we’re glad to have our relationship with Novo Nordisk
being reinforced on an additional therapeutic area” said Eric
Dessertenne, CEO of BIOCORP.
1 David C. Klonoff, MD, Smart pens will improve insulin therapy,
Journal of Diabetes Science and Technology 2018, Vol. 12(3)
Recognized for its expertise in the development and manufacture
of medical devices and delivery systems, BIOCORP has today acquired
a leading position in the connected medical device market thanks to
Mallya. This smart sensor for insulin injection pens allows
reliable monitoring of injected doses and thus offers better
compliance in the treatment of patients with diabetes. Available
for sale from 2020, Mallya spearheads BIOCORP's product portfolio
of innovative connected solutions. The company has 74 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 –
For more information, please visit www.biocorpsys.com.
version on businesswire.com: https://www.businesswire.com/news/home/20221025005531/en/
CONTACTS BIOCORP Jacques Gardette Chairman of the Board
Éric Dessertenne Chief Executive Officer
Sylvaine Dessard Marketing & Communication Director
firstname.lastname@example.org + 33 (0)6 88 69 72 85
CONTACTS ULYSSE COMMUNICATION Bruno ARABIAN
email@example.com +33 (0)6 87 88 47 26
Historical Stock Chart
Von Dez 2022 bis Jan 2023
Historical Stock Chart
Von Jan 2022 bis Jan 2023